Market Live Email

AstraZeneca's breast cancer drug gets accelerated US approval, Spire Healthcare agrees to £1.03bn takeover bid

By Iain Gilbert

Date: Monday 07 Sep 2026

(Sharecast News) - LONDON PRE-OPEN

The FTSE 100 was expected to open 18.3 points lower ahead of the opening bell on Monday, after wrapping up the previous session flat at 10,831.09.


STOCKS TO WATCH

Drugmaker AstraZeneca said on Monday that its breast cancer drug Etcamah (camizestrant),...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page